// App-Quantinova.ai

9007 : Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutationpositive non-squamous nonsmall-cell lung cancer (NSCLC): Survival follow-up results of JO25567.

Researchers

Presenter

  • Noboru Yamamoto

Principal Investigators

  • Takashi Seto

  • Makoto Nishio

  • Koichi Goto

  • Isamu Okamoto

  • Takeharu Yamanaka

  • Misa Tanaka

  • Koji Takahashi

  • Masahiro Fukuoka

  • Nobuyuki Yamamoto

Medical Centers

  • Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan

  • Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan

  • Department of Pharmacy,The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

  • Depertment of Surgical Oncology, National Cancer Center Hospital East, Chiba, Japan

  • Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

  • Department of Biostatistics Yokohama City University School of Medicine, Yokohama, Japan

  • Taiho Pharmaceutical Co., LTD., Tokyo, Japan

  • Izumi Municipal Hospital, Izumi City, Japan

  • Second Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan

Locations

  • Japan

Companies

  • Chugai Pharmaceutica

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Epidermal growth factor receptor

Drug/Treatment

  • Bevacizumab

  • Erlotinib hydrochloride

Outcome

  • Positive

Study Design

  • Randomized

  • Open Label

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved